Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1
  • Main
  • Сlinical Trials
    • Completed phase I/IIa clinical trial
    • Case studies
    • Ex-US Clinical Trials
    • US clinical trials
  • Dogs & Cats
    • Comparative Medicine and Veterinary Research
  • Elenagen
    • Elenagen is a Plasmid (Circular DNA) Encoding Gene P62/SQSTM1
    • Elenagen Reduces/Reverts Tumor Grade
    • Elenagen Changes Tumor Microenvironment
    • Elenagen Downregulates Chronic Inflammation
    • Elenagen Enhances Anti-Tumoral Immune Response
  • IP
  • Publications
  • Investors
    • One-pager
    • Slide presentation
  • Team
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
    • Careers
  • News
    • Company news
    • In the news
  • Legal
CureLab Oncology Secures Patent Protection in India
November 23, 2021
TheScientist-Russia
The Scientist: Russian Scientists Grapple with an Uncertain Future
March 30, 2022
January 31, 2022

CureLab Oncology and the American Eurasian Cancer Alliance Partner to Fight Ovarian Cancer

Partnership aims to accelerate CureLab’s clinical studies by providing access to intellectual and scientific resources that can advance research and discovery in ovarian cancer prevention and treatment strategies
AECA

BOSTON and PHILADELPHIA—January 31, 2022: CureLab Oncology,a clinical-stage biotech company, and the American Eurasian Cancer Alliance (AECA), have partnered to expand research and to fast-track next-generation therapies for ovarian cancer in Eurasia. The alliance aims to accelerate the clinical trials of CureLab Oncology’s Elenagen™, an experimental DNA therapy, by leveraging the broad reach and influence of the AECA in the region.

Since its inception in 2001, the AECA has implemented its vision of decreasing the burden of cancer in U.S. and Eurasian populations through strategic partnerships and programs that promote cancer research and enhance cancer control in the region. AECA’s reach extends across the Russian Federation, Central Asia (Kazakhstan, Uzbekistan, Kyrgyzstan, Tajikistan), Central Europe (Ukraine, Moldova, Belarus), the Baltics (Lithuania, Latvia, Estonia), and Caucasia (Armenia, Georgia, Azerbaijan).

In Belarus, for example, the AECA and CureLab Oncology have already teamed to help launch the International Gynecologic Cancer Society (IGCS) program within the country. CureLab’s ongoing clinical research studies of Elenagen therapy at the N.N. Alexandrov National Cancer Centre of Belarus have demonstrated encouraging preliminary results in triple-negative breast cancer and platinum-resistant ovarian cancer patients.

“We want to build on our program in Belarus and bring the fight against ovarian cancer to more countries in the region,” said Alexander Shneider, Ph.D., CEO of CureLab Oncology. “The AECA’s commitment to strengthening global cancer research, promoting research training and education, and translating research into policy and programs will enable us to achieve that goal. Importantly, this is a two-way highway—if not a Möbius strip. An invention made by a team of American, Israeli, and Italian scientists came to Russia and Belarus for pre-clinical and early-stage clinical development, and now we are bringing it back to the United State for phase II clinical trials.”

“For decades, AECA has been on the cutting edge of scientific and technological oncology advancements, and we’re thrilled to continue this important endeavor with CureLab Oncology,” said Dr. Sophia Michaelson, executive director of the American Eurasian Cancer Alliance.

“Leveraging AECA’s strong partnerships throughout the Eurasian region has already helped to advance this experimental treatment agenda, and we are hopeful continued research will yield results that could be beneficial for the global cancer control community.”

About the American Eurasian Cancer Alliance
The American Eurasian Cancer Alliance (AECA) aims to pool the intellectual and scientific resources of member institutions to further research and discovery in cancer prevention, treatment strategies, and palliative care. Major areas of emphasis within AECA’s profile include efforts to strengthen global cancer research, promote research training and education, and translate research into policy and programs.

About N.N. Alexandrov National Cancer Centre of Belarus
N.N. Alexandrov National Cancer Centre of Belarus, the leading cancer institution in the country, is a comprehensive scientific, educational, counseling and diagnosis-and-treatment complex with more than 30,000 patients treated per year. To read more, visit omr.by.

About Elenagen
CureLab’s lead investigational compound is code-named Elenagen. It is a DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. In animal studies and Phase I/II human trials conducted ex-US, Elenagen has shown promise in reversing tumor grade, changing the tumor microenvironment, and enhancing the anti-cancer effects of chemotherapy. Experimental results indicate a mitigation of chronic inflammation and stimulation of an immune response to the tumor.

About CureLab Oncology
CureLab Oncology Inc. is a clinical-stage immuno-oncology biotech company headquartered in the greater Boston area. CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. To learn more, visit curelaboncology.com.

Share

Related posts

November 5, 2022

Biotech Internship Opportunity! FDA/USDA liaison


Read more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics.
CureLab Oncology is committed to creating a family of revolutionary
therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product, Elenagen, is a plasmid (supercoiled circular DNA) encoding gene p62/SQSTM1. Elenagen reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (e.g. chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor.

Clinical Trials

  • The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen.
  • The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients.
  • We are now preparing Phase II Clinical Trials within the US.

Contact us

E-mail:

info@curelab.com,

Call us:

1-609-841-1201

177 HUNTINGTON
AVE FL 17
BOSTON MA 02115-3156
© 2020 CureLab Oncology.